Repetition of SH at six months (low dose fluphenazine vs. ultra low dose fluphenazine) · adults who engage in SH
It is very uncertain whether antipsychotics changes repetition of SH at six months (low dose fluphenazine vs. ultra low… compared with placebo or another comparator drug/dose (very low certainty).
1 finding from 1 review
Response to treatment (medium term) Clinically important response to treatment as defined by each study · patients with schizophrenia
VALPROATE + ANTIPSYCHOTICS may leads to higher clinically significant response: important change As defined by each… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (low certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · patients with schizophrenia
It is very uncertain whether VALPROATE + ANTIPSYCHOTICS changes leaving the study early: Acceptability of treatment Leaving the… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (very low certainty).
1 finding from 1 review
Adverse effects – leaving the study early due to adverse effects – overall tolerability – total · patients with schizophrenia
VALPROATE + ANTIPSYCHOTICS showed no clear difference in leaving the study early: Overall tolerability Leaving the study… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (low certainty).
1 finding from 1 review
Behavioural problems: agitation or aggression · patients with schizophrenia
1 finding from 1 review
Adverse effects: 1. Sedation · patients with schizophrenia
VALPROATE + ANTIPSYCHOTICS may leads to higher adverse events: Sedation Number of participants with… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (low certainty).
1 finding from 1 review
Weight gain · patients with schizophrenia
VALPROATE + ANTIPSYCHOTICS showed no clear difference in adverse events: Weight gain Number of participants with weight gain compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (low certainty).
1 finding from 1 review
Quality of life: clinically important change in quality of life · patients with schizophrenia
1 finding from 1 review
Weight gain · people with psychosis
1 finding from 1 review
Weight gain (equal or greater then 7% of baseline) · people with psychosis
1 finding from 1 review
High prolactin at any time during treatment · people with psychosis
1 finding from 1 review
Change in corrected QT · people with psychosis
1 finding from 1 review
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with schizophrenia
1 finding from 1 review
Cognitive functioning Clinically important change in cognitive functioning as defined by each study · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
It is very uncertain whether aspirin plus antipsychotics changes leaving the study early: short‐term – for any reason compared with placebo plus antipsychotics (very low certainty).
1 finding from 1 review
Adverse events: gastrointestinal – dyspeptic symptoms – self‐assessed as at least 'moderate' · patients with schizophrenia
It is very uncertain whether aspirin plus antipsychotics changes adverse events: gastrointestinal – dyspeptic symptoms –… compared with placebo plus antipsychotics (very low certainty).
1 finding from 1 review
Quality of life: clinically important change in quality of life · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Service use: change in hospital status – any change · patients with schizophrenia
It is very uncertain whether aspirin plus antipsychotics changes service use: change in hospital status – any change compared with placebo plus antipsychotics (very low certainty).
1 finding from 1 review
Adverse effects: 1. Sedation · psychosis‐induced aggression or agitation
It is very uncertain whether benzodiazepines + antipsychotics changes tranquillisation or asleep: sedation ‐ medium term ‐ +/vs… compared with same antipsychotics (very low certainty).
1 finding from 1 review
Global state: no improvement ‐ medium termAs defined in each study · psychosis‐induced aggression or agitation
Benzodiazepines + antipsychotics showed no clear difference in global state: no improvement ‐ +/vs haloperidol ‐ medium term As… compared with same antipsychotics (low certainty).
1 finding from 1 review